HeartWare International Inc. (Nasdaq: HTWR) will
not re-initiate enrollment in a halted MVAD clinical trial in November
as previously expected. The stock price plummeted $8.82 to close at $35.21.
HeartWare International will not re-initiate enrollment
October 13, 2015 at 19:33 PM EDT
